The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of December 2017. This month there is one guideline, one diagnostic guideline and one technology appraisal that impact upon primary care.
The Autism spectrum disorder in under 19s clinical guideline has been updated to include ADHD as a factor associated with an increased prevalence of autism and changed references from DCM-4 to DCM-5. The guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years and it also covers referral.
The Atrial fibrillation and heart valve disease: self-monitoring diagnostic guideline has been updated removing the recommendations for the InRatio2 PT/INR monitor as this device is no longer available.
The Naltrexone–bupropion for managing overweight and obesity technology appraisal has been published. Naltrexone–bupropion (Mysimba®) is not recommended within its marketing authorisation for managing overweight and obesity in adults alongside a reduced-calorie diet and increased physical activity.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Antiviral Medicines Authorised for Influenza Season 2017/18||Notice of Testim Discontinuation »|